All News


ThomasOtto_VetterWEB-660962-1408626201729.jpg

Recent developments demonstrate the importance of biologicals, which usually are delivered through injections, for the drug industry's future. To find out about the process of manufacturing prefilled syringes, and to learn about innovations in filling lines, Equipment and Processing Report talked to Thomas Otto, managing director of Vetter.

Following a number of serious adverse events, including infections and fatalities, Roche and Biogen Idec have suspended the late-stage development of Ocrelizumab for the treatment of rheumatoid arthritis (RA).